In a report released yesterday, Anthony Vendetti from Maxim Group reiterated a Buy rating on PAVmed (PAVM), with a price target of $5.00. The company’s shares closed last Wednesday at $1.82.
According to TipRanks.com, Vendetti is a 4-star analyst with an average return of 5.7% and a 44.0% success rate. Vendetti covers the Healthcare sector, focusing on stocks such as Milestone Scientific, Ra Medical Systems, and Sensus Healthcare.
PAVmed has an analyst consensus of Strong Buy, with a price target consensus of $5.00, implying a 170.3% upside from current levels. In a report issued on November 5, Ascendiant also initiated coverage with a Buy rating on the stock with a $5.00 price target.
See today’s analyst top recommended stocks >>
Based on PAVmed’s latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $5.48 million. In comparison, last year the company had a GAAP net loss of $3.09 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
PAVmed, Inc. is a medical device company, which develops and commercializes a pipeline of medical products. Its product portfolio includes DisappEAR, PORTIO, Caldus, Carpx, NextCath, and NextFlo. The company was founded on June 26, 2014 and is headquartered in New York, NY.
